| Name | Title | Contact Details |
|---|
Since 1970, the El Rio Community Health Center has been working to provide quality, accessible health care. Today, more than 76,000 people in the Tucson community rely on the non-profit health center as their primary source of medical and dental care. The El Rio staffs serve over 900 people per day, 76% of those served live at or below the federal poverty level. Dedicated to serving all populations including the underrepresented and uninsured, El Rio has become one of the largest non-profit, community health centers in the United States. Today, over 70,000 people access El Rio for medical and dental care. We offer quality care and help for low-income patients by using our innovative, web-based eligibility screening system, Health-e-AZ. Year after year, we work to exceed industry standards for key quality measures for preventive and chronic care. We serve the greater Tucson area and southern Arizona, improving access to care for many special population groups, including: women at risk, children, the homeless, and individuals with HIV/AIDS.
Phoenix Care Systems, Inc. is the parent company of Willowglen Academy, Inc., Bell Therapy, Inc. and Phoenix Pharmacy, Inc. Willowglen Academy has been a leader in providing community based treatment services to autistic and mentally ill children for nearly 30 years. Bell Therapy, a pioneer in the national movement to de-institutionalize mentally ill adults has been providing innovative treatment services that promote independence, dignity, and diversity, while enhancing the quality of life since 1972.
British Columbia Cancer Foundation and Research Centre is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Avera Queen of Peace Health Services is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Mitchell, SD. To find more information about Avera Queen of Peace Health Services, please visit www.averaqueenofpeace.org
Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.